Kornimate/medical-research-clean huggingface dataset:
partners in school: promoting continuity across home and school

Conditions: Autism Spectrum Disorder

Summary: partners in school is a collection of implementation strategies (e.g., communication training, problem-solving consultation) to help parents/primary caregivers and teachers of children with autism spectrum disorder implement the same practices across home and school.

we recruited a total of 48 participants (n=22 parent-teacher dyads) from urban and suburban public schools in new york, new jersey, and connecticut. teachers were matched on years of teaching experience (0-2 years, 3-5 years, 5-10 years, or 11+ years), and then randomized to the experimental condition or the control condition. the experimental condition had 13 parent-teacher dyads (n=26 participants) and the control condition had 11 parent-teacher dyads (n=22 participants). the experimental condition included the five steps of partners in school including the pre-consultation phone interview, web-based communication skills training for the parent or teacher through school talk, in-person parent-teacher conference, three weeks of implementing the same intervention with the student at home (by parents) and school (by the teacher), and a post-consultation phone interview. parents and teachers also completed surveys at the beginning and end of partners in school. the control condition had the same experiences but the parents/teachers in that condition did not receive communication skills training through school talk. one of the key outcomes is that recruitment, randomization, condition protocols, retention, and assessment of partners in school with school talk is feasible and acceptable. these findings are significant to the scientific field because they suggest that researchers can partner with public schools and train parents and teachers to communicate and collaborate effectively in order to double the dosage, intensity, and impact of evidenced-based practices for young children on the autism spectrum disorder (asd).

Eligibility criteria:
inclusion criteria: 1. must be parent/primary caregiver or full-time, lead teacher 2. must have or teach preschool, pre- kindergarten, kindergarten, or 1st grade child with asd 3. must have or teach child with asd that can see and hear 4. access to internet via wifi-enabled phone, tablet, or computer 5. must be english or spanish speaking 6. an active email - exclusion criteria: 1. parents with younger (less than preschool) or older children (in 2nd grade or above) 2. teachers who teach older than 1st grade. 3. teaching assistants
a trial evaluating the blood glucose-lowering effect of nn1250 in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial was conducted in europe. the aim of this clinical trial was to evaluate the blood glucose-lowering effect of nn1250 (insulin degludec/insulin 454) in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months * body mass index (bmi) below or equal to 35.0 kg/m2 exclusion criteria: * subject who has donated any blood or plasma in the past month or more than 500 ml within 3 months prior to screening * smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) * not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
prognostic significance of mutation type and chromosome fragility in fanconi anemia

Conditions: Fanconi Anemia

Summary: the goal of this observational study is to analyze the data included in the spanish registry of patients with fanconi anemia to better understand the natural history of the disease, identify genetic risk and prognostic factors, and identify potential therapeutic strategies.


Eligibility criteria:
inclusion criteria: * all patients in the spanish registry of patients with fanconi anemia exclusion criteria: -
the dose finding study of daoib added to tdcs for ad

Conditions: Transcranial Direct Current Stimulation; Dementia

Summary: this is a 26-week randomized, double-blind, placebo-controlled trial. we will enroll patients with amci or mild ad. all patients will receive 2 weeks of tdcs (5 sessions per week, 10 sessions in total) during the first 2 weeks of the study, and will also be allocated randomly to either of 4 treatment groups for 24 weeks: (1) dose a group; (2) dose b group; (3) dose c group; (4) placebo group. we will assess the patients every 8 weeks during the treatment period (weeks 0, 10, 18, and 26). we hypothesize that augmentation with certain dose of daoib will yield better effect than tdcs alone in improving the cognitive function, global functioning and quality of life in patients with amci or mild ad.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of alzheimer's disease or mild cognitive impairment * mmse between 10-26 * cdr 1 or 0.5 exclusion criteria: * hachinski ischemic score \> 4 * substance abuse/dependence * parkinson disease, epilepsy, dementia with psychotic features * major depressive disorder * major physical illnesses * severe visual or hearing impairment
the role of pilates, plyometrics, and their combination for children with unilateral cerebral palsy

Conditions: Cerebral Palsy

Summary: this study was conducted to compare the effect of pilates-based core strengthening (pscs) and plyometric-based muscle loading (plyoml) and their combination on postural control, balance, and mobility in children with unilateral cerebral palsy (ulcp). eighty-one children with ulcp were randomly allocated to the pscs (n = 27), plyoml (n = 27), or combined intervention (n = 27) group. participants in the three groups were assessed for postural control, balance, and mobility on the pre and post-treatment occasions.

eighty-one children with ulcp were recruited from the physical therapy outpatient clinic of college of applied medical sciences, prince sattam bin abdulaziz university, king khalid hospital, and a tertiary referral hospital, al-kharj, saudi arabia. their age ranged between 12 and 18 years, were functioning at levels i or ii according to the gross motor function classification system, and had spasticity levels 1 or 1+ per the modified ashworth scale. children were excluded if they had fixed deformities, underwent neuromuscular or orthopedic surgery in the last 12 months, submitted to botox injection in the past 6 months, had attentional neglect, and if they had cardiopulmonary problems preventing them from performing high-intense exercise training. outcome measures * postural control: the directional dynamic limit of stability (forward, backward, paretic, and non-paretic) and overall limit of stability were assessed using the biodex balance system. * balance and mobility: the community balance and mobility scale (cb\&m), functional walking test (fwt), and timed up and down stair test (tuds) were used to quantify balance and mobility capacity. interventions all groups were trained for 45 minutes, twice per week, for 12 successive weeks. the pscs group performed eight pilates exercises geared predominantly toward the core muscles. the plyoml group performed 10 plyometric exercises primarily focused predominantly on the lower body. the combined group combined the same exercises as the pscs and plyoml groups, although with half the number of sets/repetitions.

Eligibility criteria:
inclusion criteria: * unilateral cerebral palsy * age 12-18 years * motor function level i or ii according to the gross motor function classification system. * spasticity level 1 or 1+ according to the modified ashworth scale exclusion criteria: * structural deformities/contractures * musculoskeletal or neural surgery in the last year * botox injection in the last 6 months. * cardiopulmonary disorders interfere with the ability to engage in exercise training. * perceptual and/or behavioral disorders.
endodontic microsurgery with the use of l-prf block

Conditions: Apical Periodontitis; Apical Periodontal Cyst

Summary: this study evaluates the effect of leucocyte and platelet rich fibrin block (l-prf block) during endodontic microsurgery (ems) on patient's post-operative comfort and periapical bone healing in large peri-apical lesions.

this study evaluates the effect of leucocyte and platelet rich fibrin block (l-prf block) during endodontic microsurgery (ems) on patient's post-operative comfort and periapical bone healing in large peri-apical lesions. the trial design is an open randomized controlled clinical trial with two groups. half of the participants will receive ems with l-prf block (experimental group), the other half without (control group).

Eligibility criteria:
inclusion criteria * provision of informed consent * patients from 18 years old * patients in need of an ems * ems is the only option to cure the periapical lesion * a periapical lesion that has a diameter of 10mm or more in sagittal plane, frontal plane or axial plane when measured on cbct exclusion criteria * unlikely to be able to comply with the study procedures, as judged by the investigator * orthograde endodontic (re)treatment is indicated * known or suspected current malignancy * history of chemotherapy within 5 years prior to study * history of radiation in the head and neck region * history of other metabolic bone diseases * history of bleeding disorders * hiv disease * hepatitis b or c * systemic disease (osteoporosis, diabetes...)
a study of tazemetostat in combination with hmpl-689 in patients with relapsed/refractory lymphoma

Conditions: Relapsed/Refractory Lymphoma

Summary: a phase ii clinical study of tazemetostat combined with hmpl-689 in patients with r/r lymphoma. the study includes 2 phases: dose escalation phase (phase iia) and expansion phase (phase iib).

dose escalation phase (phase iia ):including 10-20 patients for dose escalation, the enrollment will continue until about 10 patients in the dose group with response, as to determine recommended phase ii dose (rp2d). dose expansion phase (phase iib):multiple expansion cohorts will be set up according to different tumor types, and about 15-20 patients will be enrolled in each cohort to further observe the anti-tumor effect of tazemetostat combined with hmpl-689 in different pathological types of r/r lymphoma. this study is expected to enroll 85-140 patients total in phase iia and phase iib.

Eligibility criteria:
criteria: inclusion criteria: 1. willing and able to give informed consent, as documented by signed icf 2. age ≥ 18 years 3. patients with histologically confirmed r/r lymphoma: • phase iia （dose escalation study）: patients with relapsed or refractory lymphoma who have failed standard treatment and have no standard treatment options • phase iib（ expansion study ）: cohort 1 (dlbcl, fl 3b) histologically confirmed dlbcl, fl 3b (including primary mediastinal b-cell lymphoma) with relapsed/refractory disease cohort 2 (fl) patients with histologically confirmed r/r fl (grade 1, 2, 3a) cohort 3 (mcl): patients with r/r mcl who had prior therapies cohort 4 (ptcl): patients with histologically confirmed r/r ptcl who have failed or cannot tolerate standard therapy 4. patients must have at least one measurable lesion 5. life expectancy ≥ 12 weeks 6. eastern cooperative oncology group (ecog) performance status of 0-2 7. adequate bone marrow function, renal function and hepatic function: 8. currently human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), or cytomegalovirus (cmv) is inactive 9. female patients of childbearing potential must agree to use a double contraception method and male patients with partners of childbearing potential must also use an effective double contraception method during the study period and for 3 months after the final dose exclusion criteria: 1. patients who have previously used ezh2 inhibitors and pi3k inhibitors, or previously could not tolerate ezh2 inhibitors or pi3k inhibitors 2. patients with brain metastases or leptomeningeal invasion 3. has thrombocytopenia, neutropenia, or anemia of grade ≥3 (per ctcae 5.0 criteria) and any prior history of myeloid malignancies, including myelodysplastic syndrome (mds / aml/mpn) 4. has abnormalities known to be associated with mds (e.g. del 5q, chr 7 abn) and multiple primary neoplasms (mpn) (e.g. jak2 v617f) observed in cytogenetic testing and dna sequencing
comparison of post-operative pain at umbilical wound after laparoscopic cholecystectomy with transumbilical versus infraumbilical incision

Conditions: Pain, Postoperative; Gallstone

Summary: this study compare outcomes (i.e. pain, wound infection, and patient satisfaction) between infra-umbilical vs. trans-umbilical incision after laparoscopic cholecystectomy

infra-umbilical wound have been used for a while with aim at improving cosmoses of the incision. formerly, standard incision for laparoscopic cholecystectomy was infra-umbilical wound. however, no study directly compare these types of incisions in term of postoperative pain, wound infection, and patient satisfaction.

Eligibility criteria:
inclusion criteria: * elective laparoscopic cholecystectomy * willing to participate exclusion criteria: * pregnancy * immunocompromised host * on continuous ambulatory peritoneal dialysis * morbid obesity (body mass index \> 35 kg/m2) * end-stage renal disease with hemodialysis dependent * ascites * uncontrolled coagulopathy
living with chronic cancer treatments (longeviti) study

Conditions: Cancer; Tyrosine Kinase Mutation; Breast Cancer; Melanoma; Multiple Myeloma; Chronic Leukemia; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Lung Cancer

Summary: people with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. the purpose of this study is to help understand how to best support people receiving these treatments.

participants ill be scheduled for an in-person, telephone or computer video interview with the researcher(s). they will be asked about their experiences receiving targeted anti-cancer treatments. then over the next 3 months, participants will be asked to think about how receiving these cancer treatments affects daily living and to create a 'metaphor'. metaphors may be composed with any mix of visual, verbal, musical or other works participants feel expresses and brings their experiences to life.

Eligibility criteria:
inclusion criteria: taking chronic targeted anti-cancer agents - exclusion criteria: -
a prospective randomized trial comparing standard ligament reconstruction tendon interposition (lrti) vs ligament reconstruction tendon interposition (lrti) with an interference screw for thumb carpometacarpal arthritis - pilot study

Conditions: Osteoarthritis

Summary: a prospective randomized trial comparing standard ligament reconstruction tendon interposition (lrti) vs ligament reconstruction tendon interposition (lrti) with an interference screw for thumb carpometacarpal arthritis

this study will be a prospective randomized trial done in a single academic center. the patients who meet the inclusion criteria and agree to participate in the trial will be scheduled for a first cmc joint procedure. the procedure, standard lrti or lrti with a biotenodesis screw, will be allocated in a randomized fashion in the operating room using a sealed opaque envelope. after the surgery the patient will be placed in a spica splint for 1-2 weeks. following suture removal, a thumb spica cast will be applied for immobilization for a total of 6 weeks of post-operative immobilisation. the potential population for this study will include all patients with first carpometacarpal joint arthritis that have failed a conservative treatment. the primary outcome will be the thumb subsidence measured as the percentage of trapezial height, which correlates with stability. subsidence will be measured on stress x-ray under a standard pinch load. secondary outcomes will be function measured in 4 different ways: the range of motion compared to the contralateral side, pinch and grip strength compared to the other side, the disabilities of the arm shoulder and hand (dash) score and the pain score on a visual analogue scale.

Eligibility criteria:
inclusion criteria: * first cmc primary osteoarthritis refractory to conservative treatment * patient \>age 18 * able to read and understand english * available for 2 year follow up exclusion criteria: * inflammatory arthritis * active infection in the first cmc joint * concomitant neuropathy * previous surgical procedure on the thumb * active or status post crps * severe ¨z ¨deformity that requires palmar plate advancement * unwilling to participate in a research project * contralateral first cmc joint surgery

Keywords: carpometacarpal joints
the effect of enamel matrix derivatives on root coverage esthetic score

Conditions: Gingival Recession; Periodontal Diseases

Summary: subepithelial connective tissue grafts (sctg) are accepted as the gold standard in covering denuded root surfaces. combining enamel matrix derivatives (emd) with periodontoplasic surgical operations is another method in covering denuded root surface. the aim of this study is to compare a sctg operation group and emd applied group in addition to sctg using complete root coverage rate and a newer method root coverage esthetic scoring system (res).

background: subepithelial connective tissue grafts (sctg) are accepted as the gold standard in covering denuded root surfaces. combining enamel matrix derivatives (emd) with periodontoplasic surgical operations is another method in covering denuded root surface. the aim of this study is to compare a sctg operation group and emd applied group in addition to sctg using complete root coverage rate and a newer method root coverage esthetic scoring system (res). methods: this is a split-mouth and controlled study. thirthy-eight class i or ii gingival recession defects at canine teeth were treated in the control (sctg) (n=19) and test groups (n=19) (sctg+emd). the root coverage esthetic score were evaluated by 2 blind periodontists 1 year after the treatment using res. the agreement between the two periodontists was assessed by kappa analysis. complete root coverage rate was evaluated for both groups. two groups were compared with statistically methods in terms of res parameters and gingival recession height /width.

Eligibility criteria:
inclusion criteria: * the patient had no systemic disease, did not smoke cigarette and tobacco products, did not have a pregnancy and breastfeeding period, had class i and class ii gingival recession according to the miller gingival classification, had a recession depth of ≥2 mm, have not had a restoration and have had an operation in the relevant dental region that had no previous gingival surgical procedure were included in this study. exclusion criteria: * systemic disease * multiple gingival recession * miller class iii and iv recessions were excluded

Keywords: gingival recession sub epithelial connective tissue graft enamel matrix derivatives root coverage aesthetic score
adagrasib in combination with nab-sirolimus in patients with advanced solid tumors and non-small cell lung cancer with a kras g12c mutation (krystal -19)

Conditions: Solid Tumor, Adult; NSCLC; Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease

Summary: this study will evaluate the safety, mtd and/or rp2d, pk, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/nsclc with a kras g12c mutation.

this study will evaluate the safety and tolerability and clinical activity of adagrasib in combination with nab-sirolimus in patients with advanced solid tumors harboring a kras g12c mutation. the phase 1 portion will enroll advanced solid tumors to establish the maximum tolerated dose (mtd) and/or to identify recommended phase 2 combinatorial doses. the phase 2 portion will enroll patients with nsclc to further evaluate the safety/tolerability and clinical activity. adagrasib is an orally available small molecule inhibitor of kras g12c. nab-sirolimus is a nanoparticle albumin-bound (nab) form of sirolimus, and sirolimus is an inhibitor of mechanistic target of rapamycin kinase (mtor, previously known as mammalian target of rapamycin).

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of solid tumor malignancy (phase 1) or nsclc (phase 2) with kras g12c mutation * unresectable or metastatic disease * no available treatment with curative intent * adequate organ function * measurable disease per recist 1.1. exclusion criteria: * history of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * history of interstitial lung disease or radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease or pneumonitis * cardiac abnormalities

Keywords: kras nsclc adagrasib kras g12c mtor nab-sirolimus fyarro abi-009
mobile educations effect on pain outcomes

Conditions: Total Joint Arthroplasty; Pain, Postoperative

Summary: the purpose of this study is to explore the clinical impact of pain management education using a mobile web-based education delivery system compared to standard education delivery. this study seeks to understand the difference between two different education delivery methodologies and the effect on the postoperative pain experience, including participation in treatment plan, knowledge, pain outcomes, and opioid requirements in patients undergoing major hip (tha) and knee (tka) arthroplasty. it is hypothesized that a real-time, interactive, mobile education system will demonstrate improved pain associated outcomes and higher patient participation when compared to the current standard education delivery method.


Eligibility criteria:
inclusion: * adult patients * over the age of 18 years * undergoing surgical intervention and inpatient care for one of the following procedures: * total hip arthroplasty (tha) (primary, bilateral, and revision) * total knee arthroplasty (tka) (primary, bilateral, unicompartmental, and revision) * fluent in the english language exclusion: * undergoing more complex hip and knee procedures such as: * implant resections with or without spacer placement * liner exchange * tha or unipolar hip arthroplasty related to repair of hip fracture. * preexisting physical or cognitive limitations that would hinder their ability to use the mobile application

Keywords: pain education information delivery mobile application